Control and challenge of COVID-19: lessons from China’s experience
2021; American Physical Society; Volume: 321; Issue: 5 Linguagem: Inglês
10.1152/ajplung.00412.2021
ISSN1522-1504
Autores Tópico(s)Viral Infections and Outbreaks Research
ResumoEditorialControl and challenge of COVID-19: lessons from China's experienceNa Zhu and Wenjie TanNa ZhuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing, China and Wenjie TanNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing, ChinaCenter for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, ChinaPublished Online:08 Nov 2021https://doi.org/10.1152/ajplung.00412.2021This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsINTRODUCTIONLARGE-SCALE PCR-BASED TESTINGNONPHARMACEUTICAL INTERVENTIONSCHALLENGESGRANTSDISCLOSURESAUTHOR CONTRIBUTIONSAUTHOR NOTESPDF (200 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat INTRODUCTION We have now been living with coronavirus disease 2019 (COVID-19) for nearly 2 years. COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified and reported to the World Health Organization (WHO) by the China Novel Coronavirus Investigating and Research Team (1). Globally, as of September 24, 2021, there have been 230,418,451 confirmed cases of COVID-19, including 4,724,876 deaths, reported to WHO (2). Although there remain a few points of indigenous transmission in individual cities, COVID-19 is currently under control in China, successfully supported by containment and suppression strategies based on combining comprehensive large-scale polymerase chain reaction (PCR)-based testing (LSPT) and nonpharmaceutical interventions (NPIs) for control and prevention (3, 4).LARGE-SCALE PCR-BASED TESTING After the initial outbreak of COVID-19 in Wuhan city, Chinese public health, clinical, and scientific communities responded rapidly. Zhu and colleagues (1) identified the pathogen of this outbreak as a novel coronavirus that falls within the subgenus β-coronavirus and the first SARS-CoV-2 stock was isolated from human airway epithelial cells. Subsequently, specific viral nucleic acid assays using RT-PCR were quickly developed for the diagnosis of SARS-CoV-2 infection (5). These assays have been widely used for detection in both laboratory and community settings and written into the national technical guidelines of China (6). "Early detection, Early reporting, Early isolation/quarantine, and Early treatment" is the mission of "4 Earlies" given by Chinese officials and were implemented quickly and thoroughly in mainland China since the COVID-19 outbreak (4, 7). The most crucial is early detection for active case finding with case management to control and sustain containment of COVID-19. Research was conducted on SARS-CoV-2 excretion and transmission to propose optimized sample collection norms for nucleic acid testing, and implementing the strategy of the "4 Earlies" through nucleic acid screening. Comprehensive, routine, and active LSPT were widely used and played a critically important role in mainland China. Once an indicator case was found or a local outbreak was identified, LSPT combined with pooled and individual sample testing was carried out population-wide (at the whole community or city level) as well as testing samples of imported goods (3). With cost-saving, readily available, and rapid PCR testing, case-finding capacity was developed in the communities of mainland China to support full reopening of local socioeconomic activities (3, 8).NONPHARMACEUTICAL INTERVENTIONS The Chinese Center for Disease Control and Prevention (China CDC) for COVID-19 Emergency Response Strategy Team described the NPIs strategies that included containment and suppression (8). A combination of self-isolation, quarantine of close contacts, and social distancing is necessary to prevent the local transmission of SARS-CoV-2 (9). Strict movement restrictions in the outbreak area and other measures (including case isolation and quarantine) began to be introduced from January 2020 in China. The use of face masks was protective for both healthcare workers and people in the community exposed to infection by SARS-CoV-2 as well as seasonal influenza (10). Guidelines from the China CDC recommend the wearing of face masks to prevent the spread of COVID-19 in crowded public areas or transportation. With everyone wearing face masks, China has used this simple and low-cost method to successfully cutoff the path of transmission and to block off the invisible infection sources of COVID-19. Mandatory and centralized quarantine was implemented for persons detected as SARS-CoV-2 positive and their close contacts. This regulation was supported by LSPT, risk assessment and early warning, cluster epidemic analysis, and analysis of the epidemiological characteristics of asymptomatic SARS-CoV-2 infections. The 5G network has made a major contribution to nationwide epidemiological risk assessment by tracking health codes, a mobile app conducted in mainland China for more information about personal exposure to risk, and mandatory health screening in public places to curb the spread of the SARS-CoV-2 (11). Big data technology for COVID-19 has played an important role in personal tracking, surveillance, and early warning (12). So the close contacts were precisely quarantined for a reasonable period. The effectiveness of outbreak containment strategies in China based on NPIs is remarkable (13).CHALLENGES LSPT and NPI were two overarching strategies used in China to prevent the spread of SARS-CoV-2 infection. The current successful control of the epidemic of COVID-19 in mainland China has benefited from the implementation of these strategies (3, 4, 8). Although case identification and management, coupled with identification and quarantine of close contacts work well, the socioeconomic costs were very high and unsustainable in the long term (14). Emerging variants result in increased transmissibility, morbidity and mortality, and breakthrough infections (15). Now China has entered the long-term prevention stage, which maintains no or minimal indigenous transmission of SARS-CoV-2 until the population is protected through immunization with safe and effective COVID-19 vaccines. There have been recent outbreaks of indigenous transmission in Nanjing City and Yangzhou City in Jiangsu province caused by breakthrough infection of the SARS-CoV-2 Delta variant (16). Hence, continuation of long-term containment measures is necessary. Vaccine effectiveness and vaccine hesitancy will be great challenges in the future. Vaccination efforts have to contend with rapidly spreading SARS-CoV-2 variants. Furthermore, as a member of the global village, China should work hand in hand with other countries, share resources and experience, strengthen cooperation, and strive to achieve the final victory in the fight against the COVID-19.GRANTS This work was suppored by the National Natural Science Foundation of China (Grant 82072296).DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONS N.Z. drafted manuscript; N.Z. and W.T. edited and revised manuscript; N.Z. and W.T. approved final version of manuscript.AUTHOR NOTESCorrespondence: W. Tan (tanwj@ivdc.chinacdc.cn). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727–733, 2020. doi:10.1056/NEJMoa2001017. Crossref | PubMed | Web of Science | Google Scholar2. World Health Organization. Weekly epidemiological update on COVID-19 (Online). https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-28-september-2021 [2021 Sep 28].Google Scholar3. Li Z, Liu F, Cui J, Peng Z, Chang Z, Lai S, Chen Q, Wang L, Gao GF, Feng Z. Comprehensive large-scale nucleic acid-testing strategies support China's sustained containment of COVID-19. Nat Med 27: 740–742, 2021. doi:10.1038/s41591-021-01308-7. Crossref | PubMed | Web of Science | Google Scholar4. Zhou L, Wu Z, Li Z, Zhang Y, McGoogan JM, Li Q, Dong X, Ren R, Feng L, Qi X, Xi J, Cui Y, Tan W, Shi G, Wu G, Xu W, Wang X, Ma J, Su X, Feng Z, Gao GF. One hundred days of coronavirus disease 2019 prevention and control in China. Clin Infect Dis 72: 332–339, 2021. doi:10.1093/cid/ciaa725. Crossref | PubMed | Web of Science | Google Scholar5. Niu P, Lu R, Zhao L, Wang H, Huang B, Ye F, Wang W, Tan W. Three novel real-time RT-PCR assays for detection of COVID-19. China CDC Wkly 2: 453–457, 2020. doi:10.46234/ccdcw2020.116. Crossref | PubMed | Google Scholar6. Chinese Center for Disease Control and Prevention. Technical guidelines for COVID-19lLaboratory testing. China CDC Wkly 2: 332–336, 2020. doi:10.46234/ccdcw2020.085. Crossref | PubMed | Google Scholar7. Wang FS, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet 395: 391–393, 2020. doi:10.1016/S0140-6736(20)30300-7. Crossref | PubMed | Web of Science | Google Scholar8. Li Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, Zhang R, An Z, Yin W, Chen W, Qin Y, Peng Z, Zhang T, Ni D, Cui J, Wang Q, Yang X, Zhang M, Ren X, Wu D, Sun X, Li Y, Zhou L, Qi X, Song T, Gao GF, Feng Z; China CDC COVID-19 Emergency Response Strategy Team. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet 396: 63–70, 2020. doi:10.1016/S0140-6736(20)31278-2. Crossref | PubMed | Web of Science | Google Scholar9. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C, Zhu H, Berah T, Eaton JW, Monod M, Ghani AC, Donnelly CA, Riley S, Vollmer MAC, Ferguson NM, Okell LC, Bhatt S; Imperial College COVID-19 Response Team. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584: 257–261, 2020. doi:10.1038/s41586-020-2405-7. Crossref | PubMed | Web of Science | Google Scholar10. Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, Yen HL, Li Y, Ip DKM, Peiris JSM, Seto WH, Leung GM, Milton DK, Cowling BJ. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 26: 676–680, 2020. doi:10.1038/s41591-020-0843-2. Crossref | PubMed | Web of Science | Google Scholar11. The Joint Prevention and Control Mechanism of the State Council National guidelines for prevention and control measures for work resumption of enterprises and in different risk areas (Online) (in Chinese). http://www.gov.cn/zhengce/content/2020-04/09/content_5500685.html [2020 Apr 7].Google Scholar12. Wu J, Wang J, Nicholas S, Maitland E, Fan Q. Application of big data technology for COVID-19 prevention and control in China: lessons and recommendations. J Med Internet Res 22: e21980, 2020. doi:10.2196/21980. Crossref | PubMed | Web of Science | Google Scholar13. Xu S, Liu P, Mei S, Lv Q, Cheng C, Lu Y, Kong D, Wu X, Wen Y, Cao B, Gao S, Xiong H, Zhao J, Huang Y, Luo Y, Feng T. Analysis of the comprehensive non-pharmaceutical interventions and measures in containing the COVID-19 epidemic in Shenzhen: a retrospective study. BMJ Open 11: e044940, 2021. doi:10.1136/bmjopen-2020-04494. Crossref | PubMed | Web of Science | Google Scholar14. The Lancet. Sustaining containment of COVID-19 in China. Lancet 395: 1230, 2020. doi:10.1016/S0140-6736(20)30864-3. Crossref | PubMed | Web of Science | Google Scholar15. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 17: 1–17, 2021. doi:10.1038/s41576-021-00408-x. Crossref | PubMed | Web of Science | Google Scholar16. Wang R, Chen J, Hozumi Y, Yin C, Wei GW. Emerging vaccine-breakthrough SARS-CoV-2 variants (Preprint). ArXiv, 2021. arXiv:2109.04509/.Google Scholar CollectionsAPS Cross-Journal CollectionsCoronavirus-Related Papers Related ArticlesWorld health day observances in November 2021: advocating for adult and pediatric pneumonia, preterm birth, and chronic obstructive pulmonary disease 08 Nov 2021American Journal of Physiology-Lung Cellular and Molecular PhysiologyCited ByMultiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis17 July 2024 | Frontiers in Public Health, Vol. 12Evaluating the Demand for Nucleic Acid Testing in Different Scenarios of COVID-19 Transmission: A Simulation Study18 March 2024 | Infectious Diseases and Therapy, Vol. 13, No. 4Neoadjuvant Chemotherapy Is Effective in Those Infected With SARS-CoV-2: The Real-World Experience of a Large Chinese Breast Cancer Center1 Jan 2024 | Journal of Breast Cancer, Vol. 27, No. 3Change from low to out‐of‐season epidemics of influenza in China during the COVID‐19 pandemic: A time series study20 June 2023 | Journal of Medical Virology, Vol. 95, No. 6Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS‐CoV‐2 Omicron variant in China13 December 2022 | Journal of Medical Virology, Vol. 95, No. 1World health day observances in November 2022: pneumonia, chronic obstructive pulmonary disease, preterm birth, and antimicrobial resistance in focusMiša Gunjak and Rory E. Morty9 November 2022 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 323, No. 5World health day observances in November 2021: advocating for adult and pediatric pneumonia, preterm birth, and chronic obstructive pulmonary diseaseRory E. Morty8 November 2021 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 321, No. 5 More from this issue > Volume 321Issue 5November 2021Pages L958-L959 Crossmark Copyright & PermissionsCopyright © 2021 the American Physiological Society.https://doi.org/10.1152/ajplung.00412.2021PubMed34643094History Received 6 October 2021 Accepted 7 October 2021 Published online 8 November 2021 Published in print 1 November 2021 Keywordscontrolcoronavirus disease 2019 (COVID-19)large-scale polymerase chain reaction (PCR)-based testing (LSPT)nonpharmaceutical interventions (NPIs)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Metrics See more details Posted by 6 X users 10 readers on Mendeley 8 CITATIONS 8 Total citations 5 Recent citations 3.27 Field Citation Ratio 0.58 Relative Citation Ratio publications8supporting0mentioning6contrasting0Smart Citations8060Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made. See more details Posted by 6 X users 10 readers on Mendeley We recommendControl and challenge of COVID-19: lesson from China experienceNa Zhu, American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021Lessons from the impact of COVID-19 on medical educational continuity and practicesCamille Vatier, Advances in Physiology Education, 2021Reply to: "Lessons from the impact of COVID-19 on medical educational continuity and practices"Mrinmayi Morje, Advances in Physiology Education, 2021"Challenge" Questions to Enhance Laboratory Experience and Student Skills: an ExampleRob L. Dean, Advances in Physiology Education, 2007Lessons from the year of CoVID - insights, projections and next steps in a high school pathophysiology classroomSowmya Anjur, Advances in Physiology Education, 2024Powered by Privacy policyGoogle Analytics settings
Referência(s)